Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

to advance Plk inhibitors into clinical development.

Volasertib is designed to inhibit the activity of Plk1, an enzyme in the Plk family that regulates cell division (mitosis).  This inhibition is intended to result in prolonged cell cycle arrest, ultimately leading to cell death (apoptosis).10

Volasertib* is not approved by the FDA; its safety and efficacy have not been established.

About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments.  Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehri
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... July 21 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... extended release tablets. This product was recently approved by ... Pharma,s Abbreviated New Drug Application (ANDA). These bupropion hydrochloride ... mg, are therapeutically equivalent to GlaxoSmithKline,s Wellbutrin SR® Extended ...
... Conn. , July 21 Cara Therapeutics, ... Series D financing of $15 million .  The ... participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, ... International Corporation and MVM Life Science Partners. In conjunction ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 3
(Date:12/19/2014)... -- A new study suggests a possible link between ... and night sweats -- and higher rates of hip ... during menopause, affecting about 60 percent of women. The ... since they then face a higher risk of weakened ... exhibit moderate or severe menopausal symptoms are more likely ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... (SAN FRANCISCO, December 6, 2008) Four studies highlighting ... sickle cell disease will be presented today at the ... in San Francisco, CA. , Results from a ... improve endothelial dysfunction, a malfunction in the inner lining ...
... The use of dexamethasone early in the treatment of children ... cancer, may help reduce the risk of relapse according to ... December 6, at 2:00 p.m., during the 50th Annual Meeting ... Additional research will be featured at the press conference that ...
... 2008) A study assessing the quality of care for ... settings will be presented at a press conference on Saturday, ... of the American Society of Hematology in San Francisco, CA. ... risk in children with sickle cell disease, as well as ...
... 6, 2008) Four studies that highlight significant advances ... forms of thrombocytopenia, a group of bleeding disorders characterized ... will be presented in a press conference on Saturday, ... Meeting of the American Society of Hematology in San ...
... a call from a biotech lab in Korea. He was told ... clone of a pet dog, his beloved family mutt, Missy. Now ... healthy puppy living the good life in Mill Valley, California. “Not ... coat feels the same, and she has some of the same ...
... for Leadership on Right to Health , ... Boston (Vocus) December 5, ... community members and experts join for a landmark town meeting titled ,HIV/AIDS ... event, which commemorates World AIDS Day and the 60th anniversary of the ...
Cached Medicine News:Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 2Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 3Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 4Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 5Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 6Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 2Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 3Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 4Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 5Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 6Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 7Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 8Health News:Cloned Canine Celebrates Her 1st Birthday 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 3Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 4Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 5Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 6